"Benzamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BENZOIC ACID amides.
| Descriptor ID |
D001549
|
| MeSH Number(s) |
D02.065.277 D02.241.223.100.100 D02.455.426.559.389.127.085
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzamides".
Below are MeSH descriptors whose meaning is more specific than "Benzamides".
This graph shows the total number of publications written about "Benzamides" by people in this website by year, and whether "Benzamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzamides" by people in Profiles.
-
CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor. Sci Rep. 2023 09 27; 13(1):16271.
-
Use of tecovirimat for mpox infection followed by JYNNEOS vaccination postinfection in a liver transplant recipient. Transpl Infect Dis. 2023 Jun; 25(3):e14030.
-
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol. 2022 08 01; 8(8):1128-1136.
-
Cardiac pericyte reprogramming by MEK inhibition promotes arteriologenesis and angiogenesis of the ischemic heart. J Clin Invest. 2022 05 16; 132(10).
-
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations. Clin Cancer Res. 2022 01 15; 28(2):249-254.
-
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 11; 21(11):1423-1432.
-
Falsely Elevated Digoxin Levels in Patients on Enzalutamide. Circ Heart Fail. 2020 07; 13(7):e007008.
-
Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2020 02; 32(4):18-26.
-
Role of Runx2 in IGF-1R?/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis. Oncogene. 2016 09 08; 35(36):4730-40.
-
The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun; 386(6):471-8.